Zacks Investment Research Downgrades Check Cap (NASDAQ:CHEK) to Hold

Christel Deskins

Check Cap (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports. According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging […]

Check Cap (NASDAQ:CHEK) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. “

Separately, HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Check Cap in a report on Thursday, May 28th.

CHEK stock opened at $0.34 on Friday. Check Cap has a fifty-two week low of $0.30 and a fifty-two week high of $2.37. The business’s 50 day moving average price is $0.43 and its two-hundred day moving average price is $0.64. The company has a market capitalization of $15.72 million and a price-to-earnings ratio of -0.25.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.12) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.01). Research analysts forecast that Check Cap will post -0.5 earnings per share for the current year.

Check Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient’s back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon’s inner surface.

Read More: Net Margin – Understanding the Different Kinds of Profit

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Check Cap Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Check Cap and related companies with MarketBeat.com’s FREE daily email newsletter.

Next Post

CIBC Innovation Banking provides Eventus with $5m growth capital financing

CIBC Innovation Banking today announced a US$5 million growth capital financing facility for Austin-based Eventus Systems Inc., a multi-award winning global trade surveillance and market risk software platform provider. The additional capital is available to support the firm’s continued strategic growth and international expansion. The company’s flagship product, […]